188 related articles for article (PubMed ID: 28432589)
1. Expression and function of ABCG2 and XIAP in glioblastomas.
Emery IF; Gopalan A; Wood S; Chow KH; Battelli C; George J; Blaszyk H; Florman J; Yun K
J Neurooncol; 2017 May; 133(1):47-57. PubMed ID: 28432589
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells.
Yin W; Xiang D; Wang T; Zhang Y; Pham CV; Zhou S; Jiang G; Hou Y; Zhu Y; Han Y; Qiao L; Tran PH; Duan W
Sci Rep; 2021 May; 11(1):10791. PubMed ID: 34031441
[TBL] [Abstract][Full Text] [Related]
3. Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
Cai CY; Zhai H; Lei ZN; Tan CP; Chen BL; Du ZY; Wang JQ; Zhang YK; Wang YJ; Gupta P; Wang B; Chen ZS
Eur J Med Chem; 2019 Oct; 179():849-862. PubMed ID: 31302589
[TBL] [Abstract][Full Text] [Related]
4. Ko143 Reverses MDR in Glioblastoma
Lustig SD; Kodali SK; Longo SL; Kundu S; Viapiano MS
Anticancer Res; 2022 Feb; 42(2):723-730. PubMed ID: 35093870
[TBL] [Abstract][Full Text] [Related]
5. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
7. ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin.
Chen L; Shi L; Wang W; Zhou Y
Oncotarget; 2017 Jun; 8(26):43237-43247. PubMed ID: 28591733
[TBL] [Abstract][Full Text] [Related]
8. ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells.
Müller P; Abdel Gaber SA; Zimmermann W; Wittig R; Stepp H
J Photochem Photobiol B; 2020 Sep; 210():111963. PubMed ID: 32795847
[TBL] [Abstract][Full Text] [Related]
9. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells.
Martín V; Sanchez-Sanchez AM; Herrera F; Gomez-Manzano C; Fueyo J; Alvarez-Vega MA; Antolín I; Rodriguez C
Br J Cancer; 2013 May; 108(10):2005-12. PubMed ID: 23632480
[TBL] [Abstract][Full Text] [Related]
10. ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.
Buks R; Brusson M; Cochet S; Galochkina T; Cassinat B; Nemazanyy I; Peyrard T; Kiladjian JJ; de Brevern AG; Azouzi S; El Nemer W
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805426
[TBL] [Abstract][Full Text] [Related]
11. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Zattoni IF; Delabio LC; Dutra JP; Kita DH; Scheiffer G; Hembecker M; Pereira GDS; Moure VR; Valdameri G
Eur J Med Chem; 2022 Jul; 237():114346. PubMed ID: 35483322
[TBL] [Abstract][Full Text] [Related]
12. microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
Tezcan G; Tunca B; Bekar A; Preusser M; Berghoff AS; Egeli U; Cecener G; Ricken G; Budak F; Taskapılıoglu MO; Kocaeli H; Tolunay S
Cell Mol Neurobiol; 2014 Jul; 34(5):679-92. PubMed ID: 24691539
[TBL] [Abstract][Full Text] [Related]
13. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.
Jin Y; Bin ZQ; Qiang H; Liang C; Hua C; Jun D; Dong WA; Qing L
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1369-76. PubMed ID: 19340456
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
15. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
[TBL] [Abstract][Full Text] [Related]
16. Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.
Bandey I; Chiou SH; Huang AP; Tsai JC; Tu PH
Oncogene; 2015 Apr; 34(14):1853-64. PubMed ID: 24793792
[TBL] [Abstract][Full Text] [Related]
17. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
18. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
19. ABCG2 expression is related to low 5-ALA photodynamic diagnosis (PDD) efficacy and cancer stem cell phenotype, and suppression of ABCG2 improves the efficacy of PDD.
Kawai N; Hirohashi Y; Ebihara Y; Saito T; Murai A; Saito T; Shirosaki T; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Shichinohe T; Li L; Hirano S; Torigoe T
PLoS One; 2019; 14(5):e0216503. PubMed ID: 31083682
[TBL] [Abstract][Full Text] [Related]
20.
Zechner M; Castro Jaramillo CA; Zubler NS; Taddio MF; Mu L; Altmann KH; Krämer SD
J Med Chem; 2023 May; 66(10):6782-6797. PubMed ID: 37154765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
